Tags

Type your tag names separated by a space and hit enter

Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy.
Maturitas 2004; 48(4):372-80M

Abstract

OBJECTIVE

To evaluate the effects of isoflavones on vasomotor symptoms and blood lipids in postmenopausal women with contraindication for conventional hormone replacement therapy (HRT).

METHODS

This prospective, double-blind and placebo-controlled study included 50 postmenopausal women randomly divided into two groups: 25 women on soy germ isoflavones (60 mg per day, capsules) and 25 women on placebo. Inclusion criteria included: non-vegetarian, non-asian women whose last menstruation dated at least 12 months prior to the beginning of the study, with FSH > 40 mIU/ml, hot flushes and contraindication for HRT, not using tamoxifen or antibiotic and no disease of the gastrointestinal tract. For 6 months, the Kupperman menopausal index (KMI), the vaginal cytological maturation value (MV) and both hormonal and lipid profiles were assessed. The t-test and analysis of variance (ANOVA) were employed to compare the two groups.

RESULTS

In both groups, a decreased KI rate was observed. However, isoflavone was significantly superior to placebo in reducing hot flushes (44% versus 10%, respectively) (P < 0.05). After 6 months, the isoflavone group showed increased estradiol levels with unchanged FSH, LH, and vaginal cytology, and a reduction of 11.8% in LDL and an increase of 27.3% in HDL (P < 0.05). In the placebo group, just a reduction in MV was observed after 6 months (P < 0.05).

CONCLUSIONS

Soy germ isoflavone exerted favorable effects on vasomotor symptoms and lipid profile, showing itself to be an interesting alternative therapy for the postmenopausal women with contraindication for conventional HRT.

Authors+Show Affiliations

Department of Gynecology and Obstetrics, Botucatu Medical School, São Paulo State University, São Paulo 18618-970, Brazil. epetri@fmb.unesp.brNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15283929

Citation

Petri Nahas, Eliana, et al. "Benefits of Soy Germ Isoflavones in Postmenopausal Women With Contraindication for Conventional Hormone Replacement Therapy." Maturitas, vol. 48, no. 4, 2004, pp. 372-80.
Petri Nahas E, Nahás Neto J, De Luca L, et al. Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy. Maturitas. 2004;48(4):372-80.
Petri Nahas, E., Nahás Neto, J., De Luca, L., Traiman, P., Pontes, A., & Dalben, I. (2004). Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy. Maturitas, 48(4), pp. 372-80.
Petri Nahas E, et al. Benefits of Soy Germ Isoflavones in Postmenopausal Women With Contraindication for Conventional Hormone Replacement Therapy. Maturitas. 2004 Aug 20;48(4):372-80. PubMed PMID: 15283929.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy. AU - Petri Nahas,Eliana, AU - Nahás Neto,Jorge, AU - De Luca,Laurival, AU - Traiman,Paulo, AU - Pontes,Anaglória, AU - Dalben,Ivete, PY - 2003/04/02/received PY - 2003/08/01/revised PY - 2003/09/05/accepted PY - 2004/7/31/pubmed PY - 2005/1/6/medline PY - 2004/7/31/entrez SP - 372 EP - 80 JF - Maturitas JO - Maturitas VL - 48 IS - 4 N2 - OBJECTIVE: To evaluate the effects of isoflavones on vasomotor symptoms and blood lipids in postmenopausal women with contraindication for conventional hormone replacement therapy (HRT). METHODS: This prospective, double-blind and placebo-controlled study included 50 postmenopausal women randomly divided into two groups: 25 women on soy germ isoflavones (60 mg per day, capsules) and 25 women on placebo. Inclusion criteria included: non-vegetarian, non-asian women whose last menstruation dated at least 12 months prior to the beginning of the study, with FSH > 40 mIU/ml, hot flushes and contraindication for HRT, not using tamoxifen or antibiotic and no disease of the gastrointestinal tract. For 6 months, the Kupperman menopausal index (KMI), the vaginal cytological maturation value (MV) and both hormonal and lipid profiles were assessed. The t-test and analysis of variance (ANOVA) were employed to compare the two groups. RESULTS: In both groups, a decreased KI rate was observed. However, isoflavone was significantly superior to placebo in reducing hot flushes (44% versus 10%, respectively) (P < 0.05). After 6 months, the isoflavone group showed increased estradiol levels with unchanged FSH, LH, and vaginal cytology, and a reduction of 11.8% in LDL and an increase of 27.3% in HDL (P < 0.05). In the placebo group, just a reduction in MV was observed after 6 months (P < 0.05). CONCLUSIONS: Soy germ isoflavone exerted favorable effects on vasomotor symptoms and lipid profile, showing itself to be an interesting alternative therapy for the postmenopausal women with contraindication for conventional HRT. SN - 0378-5122 UR - https://www.unboundmedicine.com/medline/citation/15283929/Benefits_of_soy_germ_isoflavones_in_postmenopausal_women_with_contraindication_for_conventional_hormone_replacement_therapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378512203003566 DB - PRIME DP - Unbound Medicine ER -